GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (LTS:0H22) » Definitions » Price-to-Free-Cash-Flow

BioInvent International AB (LTS:0H22) Price-to-Free-Cash-Flow : N/A (As of May. 10, 2025)


View and export this data going back to . Start your Free Trial

What is BioInvent International AB Price-to-Free-Cash-Flow?

As of today (2025-05-10), BioInvent International AB's share price is kr33.10. BioInvent International AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was kr-5.94. Hence, BioInvent International AB's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for BioInvent International AB's Price-to-Free-Cash-Flow or its related term are showing as below:

LTS:0H22's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 29.03
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

BioInvent International AB's Free Cash Flow per Share for the three months ended in Dec. 2024 was kr-1.51. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was kr-5.94.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -8.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -0.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 14.60% per year.

During the past 13 years, BioInvent International AB's highest 3-Year average Free Cash Flow per Share Growth Rate was 73.10% per year. The lowest was -128.40% per year. And the median was 4.40% per year.


BioInvent International AB Price-to-Free-Cash-Flow Historical Data

The historical data trend for BioInvent International AB's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Price-to-Free-Cash-Flow Chart

BioInvent International AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioInvent International AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioInvent International AB's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, BioInvent International AB's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Price-to-Free-Cash-Flow falls into.


;
;

BioInvent International AB Price-to-Free-Cash-Flow Calculation

BioInvent International AB's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=33.10/-5.938
=N/A

BioInvent International AB's Share Price of today is kr33.10.
BioInvent International AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.94.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

BioInvent International AB  (LTS:0H22) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


BioInvent International AB Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BioInvent International AB Business Description

Traded in Other Exchanges
Address
Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines